Mylan acquires Merck generic pharmaceutical company for $7B

TriMed Staff | | Health Imaging | Diagnostic Imaging
Mylan has completed the acquisition of Merck KGaA's generics business for $6.95 billion in an all-cash transaction.

With the acquisition, the Pittsburgh-based Mylan said it will employ more than 11,000 staff, and its product offering will now include more than 570 products.

Mylan also announced that the company will change its name from Mylan Laboratories Inc. to Mylan Inc, and it has changed its financial year to begin reporting on a calendar- year basis.

TriMed Staff

Related Content

AI rules out abnormal findings on chest X-rays, significantly reducing workloads
Older adults among the walking wounded with incident TBI
Philips moves digital pathology to the cloud with AWS
PHOTO GALLERY: What does fetal medical imaging look like?
Speaker laments radiology’s major contribution to climate change
Radiologist accuracy takes a hit overnight, especially with advanced imaging exams

Around the web

Radiology Business
The biggest challenges facing radiology business managers in 2025

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.